Residual effect of reductions in red blood cell count and haematocrit and haemoglobin levels after 10-month withdrawal of pioglitazone in patients with Type 2 diabetes

Adiponectin Regulates Bone Mass via Opposite Central and Peripheral Mechanisms through FoxO1

(2013) Daisuke Kajimura et al.   Cell Metabolism

Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies

(2013) M. Ferwana et al.   DIABETIC MEDICINE

Rosiglitazone Decreases Bone Mineral Density and Increases Bone Turnover in Postmenopausal Women With Type 2 Diabetes Mellitus

(2013) John P. Bilezikian et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Association Between Thiazolidinedione Treatment and Risk of Macular Edema Among Patients With Type 2 Diabetes

(2012) Iskandar Idris et al.   ARCHIVES OF INTERNAL MEDICINE

The effects of thiazolidinediones on human bone marrow stromal cell differentiation in vitro and in thiazolidinedione-treated patients with type 2 diabetes

(2012) George R. Beck et al.   Translational Research

Assessing the Association of Pioglitazone Use and Bladder Cancer Through Drug Adverse Event Reporting

(2011) C. Piccinni et al.   DIABETES CARE

Rosiglitazone Decreases Bone Mass and Bone Marrow Fat

(2011) Torben Harsløf et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Brain PPAR-γ promotes obesity and is required for the insulin–sensitizing effect of thiazolidinediones

(2011) Min Lu et al.   NATURE MEDICINE

A role for central nervous system PPAR-γ in the regulation of energy balance

(2011) Karen K Ryan et al.   NATURE MEDICINE

Thiazolidinediones induce osteocyte apoptosis and increase sclerostin expression

(2010) G. Mabilleau et al.   DIABETIC MEDICINE

Thiazolidinedione Use and the Longitudinal Risk of Fractures in Patients with Type 2 Diabetes Mellitus

(2010) Zeina A. Habib et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Safety and Tolerability of Pioglitazone in High-Risk Patients with Type 2 Diabetes

(2009) John Dormandy et al.   DRUG SAFETY